ATE439864T1 - Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie - Google Patents

Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie

Info

Publication number
ATE439864T1
ATE439864T1 AT02805243T AT02805243T ATE439864T1 AT E439864 T1 ATE439864 T1 AT E439864T1 AT 02805243 T AT02805243 T AT 02805243T AT 02805243 T AT02805243 T AT 02805243T AT E439864 T1 ATE439864 T1 AT E439864T1
Authority
AT
Austria
Prior art keywords
amino acids
units
amino
oligopeptides
methacryloylated
Prior art date
Application number
AT02805243T
Other languages
German (de)
English (en)
Inventor
Karel Ulbrich
Tomas Etrych
Blanka Rihova
Marketa Jelinkova
Marek Kovar
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Application granted granted Critical
Publication of ATE439864T1 publication Critical patent/ATE439864T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02805243T 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie ATE439864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20014653A CZ293787B6 (cs) 2001-12-20 2001-12-20 pH senzitivní polymerní konjugáty antracyklinového kancerostatika pro cílenou terapii
PCT/CZ2002/000070 WO2003053473A2 (en) 2001-12-20 2002-12-20 Ph-sensitive polymeric conjugates of an anthracycline drug

Publications (1)

Publication Number Publication Date
ATE439864T1 true ATE439864T1 (de) 2009-09-15

Family

ID=5473644

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02805243T ATE439864T1 (de) 2001-12-20 2002-12-20 Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie

Country Status (18)

Country Link
US (1) US7919076B2 (enExample)
EP (2) EP1782833A3 (enExample)
JP (1) JP4718117B2 (enExample)
KR (1) KR20040076874A (enExample)
AT (1) ATE439864T1 (enExample)
AU (1) AU2002366715A1 (enExample)
CA (1) CA2470976A1 (enExample)
CZ (1) CZ293787B6 (enExample)
DE (1) DE60233434D1 (enExample)
DK (1) DK1463529T5 (enExample)
EA (1) EA007353B1 (enExample)
ES (1) ES2331303T3 (enExample)
HU (1) HUP0500541A3 (enExample)
PL (1) PL216518B1 (enExample)
PT (1) PT1463529E (enExample)
SI (1) SI1463529T1 (enExample)
SK (1) SK2912004A3 (enExample)
WO (1) WO2003053473A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ294996B6 (cs) * 2003-07-16 2005-04-13 Ústav Makromolekulární Chemie Av Čr Reaktivní polymery a kopolymery na bázi N-(2-hydroxypropyl)methakrylamidu, způsob jejich přípravy a jejich použití pro syntézu polymerních léčiv, pro modifikaci biologicky aktivních proteinů a přípravu systémů pro dopravu genů
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
US7812051B2 (en) 2004-08-11 2010-10-12 Arqule, Inc. Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential
CZ2005558A3 (cs) * 2005-09-05 2007-04-04 Zentiva, A. S. Zpusob prípravy polymerních konjugátu doxorubicinu s pH-rízeným uvolnováním léciva
CZ2006207A3 (cs) * 2006-03-28 2008-01-16 Zentiva, A. S. Micelární nosiče léčiv s protinádorovou aktivitou
CZ2006505A3 (cs) * 2006-08-09 2008-04-09 Zentiva, A. S. Polymerní konjugáty doxorubicinu s pH-rízeným uvolnováním léciva a zpusob jejich prípravy
EP2518495A3 (en) * 2006-08-09 2013-11-27 Sumitomo Bakelite Company, Ltd. Sugar chain-capturing substance and use thereof
CZ298945B6 (cs) * 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
DK2152686T3 (en) 2007-04-30 2015-01-12 Arqule Inc HYDROXYSULFONAT OF quinone compounds AND THEIR USES
CZ301288B6 (cs) * 2008-10-23 2009-12-30 Zentiva, A. S Polymerní prípravek se synergickým úcinkem pri lécbe nádorových onemocnení
CZ302830B6 (cs) * 2009-12-15 2011-11-30 Ústav makromolekulární chemie AV CR, v.v.i. Vysokomolekulární polymerní nosice léciv odvozené od dendrimeru a jejich konjugáty s lécivy pro lécbu zejména pevných nádoru
EP3069715A1 (en) 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
WO2018071767A1 (en) 2016-10-14 2018-04-19 University Of Utah Research Foundation Antibody-polymer-drug conjugates
WO2020214858A1 (en) * 2019-04-17 2020-10-22 Avidea Technologies, Inc. Compositions and methods of manufacturing star polymers for ligand display and/or drug delivery
CZ309828B6 (cs) * 2019-10-09 2023-11-15 I.T.A.-Intertact S.R.O. Fluorescenční polymer, fluorescenční sonda a konjugační sada pro pokročilé funkční analýzy buněk v hematologii, imunologii a mikrobiologii, způsob jejich přípravy a jejich použití
KR20220092565A (ko) * 2019-10-30 2022-07-01 씨아이에스 파르마 에이쥐 활성제를 전달하기 위한 생체 적합성 중합체 약물 담체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs

Also Published As

Publication number Publication date
DE60233434D1 (de) 2009-10-01
HUP0500541A2 (hu) 2005-09-28
US20060057099A1 (en) 2006-03-16
HUP0500541A3 (en) 2011-08-29
ES2331303T3 (es) 2009-12-29
EP1782833A3 (en) 2008-03-19
SI1463529T1 (sl) 2010-01-29
KR20040076874A (ko) 2004-09-03
EP1463529B1 (en) 2009-08-19
JP4718117B2 (ja) 2011-07-06
CA2470976A1 (en) 2003-07-03
PL216518B1 (pl) 2014-04-30
WO2003053473A3 (en) 2004-04-29
SK2912004A3 (en) 2004-12-01
AU2002366715A8 (en) 2003-07-09
CZ20014653A3 (cs) 2003-08-13
EP1463529B9 (en) 2011-03-23
PT1463529E (pt) 2009-11-03
ES2331303T9 (es) 2011-08-18
US7919076B2 (en) 2011-04-05
EP1782833A2 (en) 2007-05-09
EA007353B1 (ru) 2006-10-27
PL370719A1 (en) 2005-05-30
CZ293787B6 (cs) 2004-07-14
EA200400802A1 (ru) 2005-02-24
DK1463529T3 (da) 2009-10-19
DK1463529T5 (da) 2011-06-27
JP2005519044A (ja) 2005-06-30
WO2003053473A2 (en) 2003-07-03
EP1463529A2 (en) 2004-10-06
AU2002366715A1 (en) 2003-07-09

Similar Documents

Publication Publication Date Title
ATE439864T1 (de) Ph-empfindliche polymere konjugate eines karzinostatischen anthracyclin-arzneimittels für die gezielte therapie
US7893023B2 (en) Prodrugs activated by plasmin and their use in cancer chemotherapy
TR200200252T2 (tr) Şimerik polipeptidler, bunların üretimi için yöntem ve kullanımı
CY1117065T1 (el) Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων
BR0013577A (pt) Efetores de dipeptidil peptidase iv para uso tópico
RU2010119521A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
CY1108465T1 (el) Μεθοδος συνθεσης πεπτιδιων στερεης φασης
PA8497801A1 (es) Conjugados de eritropoyetina
BR9406725A (pt) Amplificação do sistema de ingestão de vitamina b12 usando polímeros
NO993866L (no) Legemiddel mot lymfatiske tumorer
JP2005519044A5 (enExample)
ATE118686T1 (de) Biologisch wirksame polymere arzneistoffderivate.
ATE238348T1 (de) Aus thymischen hormonen abstammende peptid konjugierte, deren verwendung als medikamente und aus deren enthaltende zusammensetzungen
PT2046813E (pt) Derivados de metotrexato que se ligam a proteínas e medicamentos contendo estes
DE60216243D1 (de) Synthetische humane peptide und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von systemischem lupus erythematodes
ES8103026A1 (es) Un procedimiento para la preparacion de un peptido
Ulbrich et al. Polymer‐bound derivatives of sarcolysin and their antitumour activity against mouse and human leukaemia in vitro
Pechar et al. Conjugates of Antibody‐Targeted PEG Multiblock Polymers with Doxorubicin in Cancer Therapy
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
Říhová et al. Targetable photoactivatable drugs
Miklán et al. Cell-penetrating and targeting peptide conjugates of antitumor drugs: Synthesis, chemical and in vitro biological characterization
RU95105590A (ru) Гепатотропные конъюгаты антивирусных лекарственных средств, их носители, содержащие их фармацевтические композиции, способ получения конъюгатов
van Heeswijk et al. Dept. of Chem. Technology, Twente University of Technol-ogy, Enschede, Dept. of Internal Medicine, Free Univer-sity Hospital, Amsterdam; Radiobiological Institute TNO
JPH06157347A (ja) 選択性制癌剤

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1463529

Country of ref document: EP